BOB: Bayesian optimal design for biosimilar trials with co-primary endpoints
From MaRDI portal
Publication:6629374
DOI10.1002/SIM.9571zbMATH Open1547.62188MaRDI QIDQ6629374FDOQ6629374
Authors: Xiaohan Chi, Zhangsheng Yu, Ruitao Lin 
Publication date: 29 October 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
Cites Work
- Testing Statistical Hypotheses of Equivalence and Noninferiority
- Bioequivalence trials, intersection-union tests and equivalence confidence sets. With comments and a rejoinder by the authors
- Practical Bayesian Guidelines for Phase IIB Clinical Trials
- Robust meta‐analytic‐predictive priors in clinical trials with historical control information
- Incorporating historical information in biosimilar trials: challenges and a hybrid Bayesian-frequentist approach
- Bayesian design of biosimilars clinical programs involving multiple therapeutic indications
- A calibrated power prior approach to borrow information from historical data with application to biosimilar clinical trials
This page was built for publication: BOB: Bayesian optimal design for biosimilar trials with co-primary endpoints
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6629374)
